



GENERIC
PHARMASEC LTD

(Formerly Known as Adi Rasayan Limited)

CIN : L24231MH1992PLC323914

104 & 105 1st Floor Gundecha Industrial Premises Co-op Soc.
Ltd., Akurli Road, Kandivali (East) Mumbai - 400101.

+91- 86555 50242

compliance@genpharmasec.com
info@genpharmasec.com

www.genpharmasec.com

Date: 12th August 2021

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
14th Floor, P.J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sir/ Madam,

Subject: - Outcome of Board Meeting held on Thursday, 12th August, 2021 at 05.00 P. M.
Reference: BSE Scrip Code: 531592

Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Thursday, 12th August 2021 at 05.00 p.m. has Considered and Approved the following:

1. The Un-Audited Financial Results along with Limited Review Report for the Quarter ended 30th June 2021 prepared in terms of IND-AS, pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement,) Regulation 2015.
2. Appointment of Ms. Nikhita Pais, as an Additional Director (Non -Executive Independent) on the Board of the Company w.e.f August 12, 2021 to hold office till the conclusion of the next Annual General Meeting and subject to the approval of the members in the ensuing General Meeting, for appointment as an Independent Director to hold office for a term up to 5 (five) Consecutive years from August 12, 2021.

Brief Profile of Ms. Nikhita Pais and the details required under Regulation 30 of Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is given in the enclosed Annexure.

3. Considered and approved the appointment of M/s. Meenakshi Manish Jain & Associates, Chartered Accountants, as an Internal Auditor of the Company for financial year 2021-2022.
4. Resignation of Mrs. Veda Adhatrao Bhushan [DIN 07149680] from the post of Non - executive Independent Director of the Company and consented to relieve her of her responsibilities w.e.f August 12, 2021.

V. Adhatrao



5. Appointment of Mr. Vivek Anand Oberoi, as Chief Strategy Officer (CSO) for proposed international business of the Company.


Vivek Anand Oberoi will work as an advisor and will also have the responsibility of formulating International corporate strategy for the Company.

Kindly take the same on your records.

Thanking You,

Yours Truly,

For Generic Pharmasec Limited



Ulhas Narayan Deosthale
Managing Director & CEO
DIN: 09215291



Annexure

Details under Regulation 30 of SEBI (LODR) Regulations, 2015 read along with SEBI circular CIR/CFD/CMD/4/2015 dated September 09, 2015.

Name	Ms. Nikhita Pais
Reason for change	Appointment
Date of appointment	12 th August, 2021
Qualification	LLM; BLS. LLB.; CS
Experience & Expertise	International trade and investment related advisory with focus on market access and trade defense
Shareholding, if any in the Company	NIL
Disclosure of relationships between Directors (in case of appointment as a Director)	No Relation

Nikhita Pais



GENERIC PHARMASEC LIMITED
Formerly known as ADI RASAYAN LTD
Statement of Standalone Un Audited Results for the Quarter and Year Ended June 30, 2021

(Rs. In Lakhs)


Particulars	Quarter Ended			Year Ended
	31/06/2021	31/03/2021	30/06/2020	31/03/2021
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1 Revenue from Operations	810.28	676.10	824.70	2,130.75
2 Other Income	5.87	(5.49)	16.88	32.78
3 Total Revenue (1 + 2)	816.15	670.60	841.58	2,163.53
4 Expenses				
Cost of materials consumed		-	-	-
Purchase of stock-in-trade	1,112.56	820.43	610.90	2,342.12
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(342.24)	(426.61)	115.63	(422.08)
Employee benefits expense	5.08	4.94	3.55	18.75
Depreciation and amortisation expense	0.34	0.33	0.27	1.25
Other expenses	20.78	9.63	17.13	72.54
Total expenses	796.52	408.73	747.48	2,012.58
5 Profit/(Loss) Before Exceptional Item and Tax (3-4)	19.64	261.88	94.10	150.95
6 Exceptional items		-	-	-
7 Profit/(Loss) Before Tax (5-6)	19.64	261.88	94.10	150.95
8 Tax expense				
(1) Current Tax	5.11	11.27	-	25.20
(2) Deferred Tax		(0.17)	-	(0.10)
9 Profit / (Loss) from continuing operations (7 - 8)	14.53	250.77	94.10	125.86
10 Profit / (Loss) from discontinuing operations		-	-	-
11 Tax expense of discontinuing operations		-	-	-
12 Profit/(loss) from Discontinuing operations (after tax)		-	-	-
13 Profit (Loss) for the period (9+12)	14.53	250.77	94.10	125.86
14 Other Comprehensive income;				
A (i) Items that will not be reclassified to profit or loss	(103.14)	(242.25)	56.29	(413.04)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
15 Total Comprehensive Income for the period (13+14) (Comprising profit/ (loss) and other Comprehensive Income for the period	(88.61)	8.52	150.39	(287.19)
16 Earnings per equity share (for discontinued & continuing operations) of face value of Rs. 10 each (Refer Note. 6)				
(a) Basic	0.01	0.09	0.03	0.05
(b) Diluted	0.01	0.09	0.03	0.05

Notes:

- The above result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 12th August, 2021. In terms of SEBI circular CIR/CFD/CMD/56/2016 dated 28th May, 2016, the Company declares that the statutory auditors have issued Audit Report with an unmodified opinion.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent
- The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108) in "Annexure-I".
- The figures for the quarter ended March 31, 2021 as reported in the financial results, are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures upto 30.06.2021. Also, the figures upto 30.06.2021 had only been reviewed and not subjected to audit.
- Previous period figures have been regrouped/reclassified as considered necessary to facilitate comparison.

For and on behalf of the Board of
GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)

Ulihas Narayan Deosthale
(Ulihas Narayan Deosthale)
Director & CFO
DIN : 09215291



PLACE : MUMBAI
DATE : 12/08/2021


GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)
"ANNEXURE - I"


Statement of Unaudited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter Ended 30th June, 2021

Particulars	(Rs. In Lakhs)			
	Quarter Ended			Year Ended
	30/06/2021 (Unaudited)	31/03/2021 (Audited)	30/06/2020 (Unaudited)	31/03/2021 (Audited)
Segment Revenue				
Pharmaceuticals	795.43	639.44	824.70	2,079.93
Trading in Securities	14.85	31.16	-	50.40
Total Revenue	810.28	670.60	824.70	2,130.33
Segment Results (Profit before tax and interest)				
Pharmaceuticals	74.24	118.62	94.09	236.58
Trading in Securities	(52.48)	148.77	-	(53.75)
Total	21.75	267.39	94.09	182.83
Less				
(i) Unallocated Finance Cost	-	-	-	-
(ii) Other unallocable expenditure net of unallocable income	2.12	12.50	-	64.98
(iii) Inter Segment Eliminations	-	-	-	-
Profit Before Tax	19.64	254.89	94.09	117.85
Segment Assets				
Pharmaceuticals	1,296.87	1,310.96	946.81	1,310.96
Trading in Securities	550.91	340.11	-	340.11
Un-Allocated	1,165.60	1,130.89	1,884.66	1,130.89
Total	3,013.38	2,781.96	2,831.46	2,781.96
Segment Liabilities				
Pharmaceuticals	977.30	711.61	229.58	711.61
Trading in Securities	-	-	-	-
Un-Allocated	2,036.08	2,070.34	2,601.88	2,070.34
Total	3,013.38	2,781.96	2,831.46	2,781.96

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

For and on behalf of the Board of
GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)


(Ulhas Narayan Deosthale)
Director & CFO
DIN : 09215291



PLACE : MUMBAI
DATE : 12/08/2021

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of
GENERIC PHARMASEC LIMITED

We have reviewed the accompanying statement of unaudited financial results of **GENERIC PHARMASEC LIMITED** for the quarter ended 30th June, 2021 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rule, 2015, as amended and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Indian accounting Standards ("Ind AS") prescribed under s.133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Abhishek S Tiwari & Associates
Chartered Accountants




Abhishek Tiwari
Proprietor
M.No.155947

Place of signature: Mumbai
Date: 12.08.2021

UDIN: 21155947AAAACS4081